Am Fam Physician. 2022;105(6):656-658
Author disclosure: No relevant financial relationships.
Tenapanor (Ibsrela) is labeled for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults.1 It is a sodium/hydrogen exchanger 3 inhibitor that acts on the surface of the small intestine and colon to block the absorption of dietary sodium, resulting in increased water secretion. This leads to more frequent and softer bowel movements. Tenapanor also decreases visceral hypersensitivity, leading to reduced abdominal pain.
Drug | Dosage | Dose form | Cost of full course |
---|---|---|---|
Tenapanor (Ibsrela) | 50 mg twice daily, taken immediately before first meal of the day and before dinner | 50-mg tablets | Price not yet available |
Safety
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available